Hikma Pharma To Buy Rival's Injectable Biz For $135M
Hikma said on Monday it has agreed to buy units of Xellia, a Danish provider of anti-infective treatments and critical care therapies, for up to $185 million, as the U.K. pharmaceutical...To view the full article, register now.
Already a subscriber? Click here to view full article